Oncomatryx Biopharma Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
14
- Investments
-
1
Oncomatryx Biopharma General Information
Description
Developer of stroma-targeted precision drugs and diagnostics intended to fight against invasive tumours. The company is aimed at discovering new mechanisms and proteins in the peritumoral stroma, the cells, and the extracellular matrix that surround the tumour and facilitate its invasiveness, resistance to treatment, and metastasis, enabling doctors to diagnose, prognosis, and fight against tumour invasiveness.
Contact Information
Website
www.oncomatryx.comCorporate Office
- Parque Tecnológico de Bizkaia 801B-2P
- 48160 Derio
- Spain
Corporate Office
- Parque Tecnológico de Bizkaia 801B-2P
- 48160 Derio
- Spain
Oncomatryx Biopharma Timeline
Oncomatryx Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oncomatryx Biopharma Patents
Oncomatryx Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4789684-A1 | Anti-endoglin antibody-drug conjugates | Pending | 05-Feb-2025 | ||
| EP-4789685-A1 | Anti-endoglin antibody-drug conjugates | Pending | 05-Feb-2025 | ||
| WO-2026167104-A1 | Anti-endoglin antibody-drug conjugates | Pending | 05-Feb-2025 | ||
| WO-2026167116-A1 | Anti-endoglin antibody-drug conjugates | Pending | 05-Feb-2025 | ||
| EP-4759329-A1 | Combination therapy for the treatment of metastatic cancer | Pending | 10-Dec-2024 | A61K47/6803 |
Oncomatryx Biopharma Signals
Oncomatryx Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Oncomatryx Biopharma Investments (1)
Oncomatryx Biopharma’s most recent deal was a Buyout/LBO with Tube Pharmaceuticals. The deal was made on 08-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tube Pharmaceuticals | 08-Mar-2023 | Buyout/LBO | Biotechnology |
Oncomatryx Biopharma FAQs
-
When was Oncomatryx Biopharma founded?
Oncomatryx Biopharma was founded in 2009.
-
Where is Oncomatryx Biopharma headquartered?
Oncomatryx Biopharma is headquartered in Derio, Spain.
-
What is the size of Oncomatryx Biopharma?
Oncomatryx Biopharma has 36 total employees.
-
What industry is Oncomatryx Biopharma in?
Oncomatryx Biopharma’s primary industry is Drug Discovery.
-
Is Oncomatryx Biopharma a private or public company?
Oncomatryx Biopharma is a Private company.
-
What is Oncomatryx Biopharma’s current revenue?
The current revenue for Oncomatryx Biopharma is .
-
How much funding has Oncomatryx Biopharma raised over time?
Oncomatryx Biopharma has raised $146M.
-
Who are Oncomatryx Biopharma’s investors?
Basque Government, Kutxa Fundazioa, European Innovation Council, INNVIERTE SICC, and Bilbao Bizkaia Kutxa Fundación Bancaria are 5 of 7 investors who have invested in Oncomatryx Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process